| Literature DB >> 31037971 |
Pushpendra Goswami1, Esther N Oliva2, Tatyana Ionova3, Roger Else4, Jonathan Kell5, Adele K Fielding6, Daniel M Jennings7, Marina Karakantza8, Saad Al-Ismail9, Jack Lyness9, Graham P Collins10, Stewart McConnell8, Catherine Langton8, Magda Jabbar Al-Obaidi11, Metod Oblak11, Sam Salek1.
Abstract
Aim: To determine measurement equivalence of paper and electronic application of the hematological malignancy-patient-reported outcome (HM-PRO), a specific measure for the evaluation of patient-reported outcomes in HMs. Patients & methods: Following International Society of Pharmacoeconomics and Outcomes Research ePRO Good Research Practice Task Force guidelines, a total of 193 adult patients with different HMs were recruited into a multicenter prospective study. The paper and the electronic version of the instrument were completed in the outpatient clinics in a randomized crossover design with a 30 min time interval to minimize the learning effect. Those who completed the paper version first, completed the electronic version after 30 min and vice versa. Instrument version and order effects were tested on total score of the two parts of the HM-PRO (Part A: quality of life and Part B: signs & symptoms) in a two-way ANOVA with patients as random effects. Intraclass correlation coefficients (95% CI) and Spearman's rank correlation coefficients were used to evaluate test-retest reliability and reproducibility. The effects of instrument version and order were tested on total score of the two parts of HM-PRO.Entities:
Keywords: HM-PRO; hematological malignancy; paper/electronic PRO
Mesh:
Year: 2019 PMID: 31037971 DOI: 10.2217/cer-2018-0108
Source DB: PubMed Journal: J Comp Eff Res ISSN: 2042-6305 Impact factor: 1.744